新基制药(CELG)

坐以待币2015-08-24 22:51

$新基(CELG)$ 生物制药永远是最强者。查看全文

tiger-in-motion2015-08-24 20:44

盘前三大指数已经让想做空的朋友 也只能旁观
常识还是战胜了人性的恐惧， 股市崩溃 2001, 1987, 2009 这种 股市冰河发生的概率 和背后的原因 和今天的世界经济基本面和 各个国家目前的货币政策 还是有所不同，
准备 这两天 连续 买入 做一个飞蛾扑火的 傻瓜：
目标 分别从 防守型的股...查看全文

王伟CFA美股MCORLEO2015-08-15 01:26

$新基(CELG)$ 要90多买$ Juno Therapeutics (JUNO)$ 股份还算数不查看全文

Pnmk2015-08-07 22:38

$新基(CELG)$ 到2019年，CELG会是大生物科技里增长最快的。如果喜欢IBB板块，或者买IBB，XBI 或者买CELG作为长线投资。这个板块每年都有1次10-20%回调。加息对没有正现金流的小公司影响严重，而对CELG之类的，反倒是买入的机会。查看全文

Jeffwan-美股新手2015-07-28 12:50

忙了两个月工作，也么的时间关注股票，回归回归，抛掉了所有A股，这次算真是见识了，最后算下来也亏损了不少，为自己的没纪律买单。重新开始美股，每日总结，从$Horizon Pharma (HZNP)$ $新基(CELG)$ 开始，加油！查看全文

新基的评级信息汇总

深思远见2015-07-24 22:32

$新基(CELG)$近期评级信息如下：
20150721 Piper Jaffray 提高目标价， 评级：， 目标价：$144.00 -> $160.00
更多分析和资讯，请关注微-信-公-众-号 stock_tong查看全文

好祖2015-07-22 00:09

ipo解禁压力不假，不过微博截图里的话就有些风趣了。消息是先行支付1.5亿，之后购入8.5亿股，占10%。但celg最看重的是未来合作marketing juno的药物产品，盈利按照7成分得，同时可选择在十年内的pre-opt window进一步获取20%股份的权利。研发能不能成功没人知道，不过千亿公司的投资远非想象的简单查看全文

One month after lock-up expiry

name9982015-07-21 23:42

$ Juno Therapeutics (JUNO)$
Hope those who chased this name after the recent $新基(CELG)$ collaboration information knows about this:
80% of locked-up shares have expired (highest as far as I know in recent biotech names). I have mentioned this before.
IMHO, the l...查看全文

BlackPuma2015-07-17 03:19

$Arena Pharmaceuticals(ARNA)$ $新基(CELG)$ 评级机构Tier 1对RCPT和CELG的并购进行评价内容显示这一并购案对ARNA有利查看全文

lochaon2015-07-16 03:09

Having both $Habit Restaurants(HABT)$ and $新基(CELG)$ in my porfolio is a pretty mixed feeling查看全文

$新基制药(CELG)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013792  Size: 69 KB 网页链接

$新基制药(CELG)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013796  Size: 42 KB 网页链接

$新基制药(CELG)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-19-022527  Act: 34  Size: 15 KB 网页链接

$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022225  Act: 33  Size: 20 KB 网页链接

$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022228  Act: 33  Size: 20 KB 网页链接

$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022200  Act: 33  Size: 20 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022201  Act: 33  Size: 39 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022206  Act: 33  Size: 39 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022210  Act: 33  Size: 39 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022217  Act: 33  Size: 39 KB 网页链接